Xilio Therapeutics (XLO)

• Market cap: $41.3M
• 1 day: -0.86%
• 5 days: -2.13%
• 1 month: -5.46%
• 3 months: 22.8%
• 6 months: 4.05%
• Year to date: -25.54%
• 1 year: -37.27%
• 5 years: -95.02%
• 10 years: -95.02%
• Sector: Healthcare
• Industry: Biotechnology

About: Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Employees: 73